Breaking News

Saturday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Esperion participates in a conference call with Credit Suisse » 16:13
04/04/20
04/04
16:13
04/04/20
16:13
ESPR

Esperion

$30.93 /

-2.13 (-6.44%)

Conference call with…

Conference call with management will be held on April 9 at 11 am hosted by Credit Suisse.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
Initiation
Fly Intel: Top five analyst initiations » 10:17
04/01/20
04/01
10:17
04/01/20
10:17
ZM

Zoom Video

$139.52 /

-6.56 (-4.49%)

, BTAI

BioXcel Therapeutics

$20.98 /

-1.42 (-6.34%)

, PROF

Profound Medical

$9.35 /

-0.25 (-2.60%)

, AEO

American Eagle

$7.16 /

-0.775 (-9.77%)

, HBI

Hanesbrands

$7.42 /

-0.44 (-5.60%)

, ESPR

Esperion

$30.89 /

-0.51 (-1.62%)

, KNSA

Kiniksa

$15.26 /

-0.16 (-1.04%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Neutral at DA Davidson. 2. BioXcel Therapeutics (BTAI) initiated with a Buy at BofA. 3. Profound Medical (PROF) initiated with an Outperform at Cowen. 4. American Eagle (AEO) and Hanesbrands (HBI) initiated with a Market Perform at Raymond James. 5. Esperion (ESPR) and Kiniksa (KNSA) initiated with a Buy at BofA. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Esperion initiated with a Buy at BofA » 06:32
04/01/20
04/01
06:32
04/01/20
06:32
ESPR

Esperion

$31.40 /

-2.6 (-7.65%)

BofA analyst Geoff…

BofA analyst Geoff Meachem initiated coverage of Esperion with a Buy rating and $50 price target. The company is gearing up for its first product launch, which he thinks will lead investors to revisit the name sooner than other small-to-midcap biopharma stocks, Meachem said.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Hot Stocks
Esperion announces commercial availability of Nexletol tablet in the U.S. » 16:40
03/30/20
03/30
16:40
03/30/20
16:40
ESPR

Esperion

$34.00 /

-1.28 (-3.63%)

Esperion announced that…

Esperion announced that Nexletol tablet, an oral, once-daily, non-statin LDL-Cholesterol, or LDL-C, lowering medicine is now available in U.S. pharmacies. Esperion is committed to respecting the valuable time of healthcare providers in the current environment while also remaining steadfast to the patients awaiting new options to manage their bad cholesterol. Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The effect of Nexletol on cardiovascular morbidity and mortality has not been determined.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion announces data presentations of NEXLETOL, NEXLIZET Tablet » 09:56
03/28/20
03/28
09:56
03/28/20
09:56
ESPR

Esperion

$35.28 /

-2.07 (-5.54%)

Esperion announced that…

Esperion announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 study of NEXLIZET were presented at the American College of Cardiology's 69th Scientific Session Together with World Congress of Cardiology. A poster titled "Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed Combination Drug Product vs Ezetimibe Alone or Placebo in Patients with Type 2 Diabetes and Hypercholesterolemia" highlighted that in the Phase 2 study, NEXLIZET significantly lowered LDL-Cholesterol by a mean 40% compared to placebo, reduced high-sensitivity C-reactive protein by 25% compared to baseline and resulted in no worsening of glycemic control. The incidence of adverse events rates were generally comparable to placebo. In addition, a poster, titled "Factors Influencing Bempedoic Acid-Mediated Reductions in High-sensitivity C-reactive Protein: Analysis of Pooled Patient-level Data from 4 Phase 3 Clinical Trials" highlighted that in the pooled Phase 3 studies, NEXLETOL significantly lowered hsCRP in patients with hypercholesterolemia regardless of the presence or intensity of background statin therapy. In patients whose hsCRP levels were greater than 2 mg/L at baseline, the analysis showed NEXLETOL significantly reduced this marker of inflammation by 42% at 12 weeks. The third poster was titled "Bempedoic Acid Efficacy and Safety in Patients at High Risk for CVD Treated with or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials" and the pooled analysis showed that in the Phase 3 studies, NEXLETOL provided significant additional LDL-C lowering as well as significantly lowered other lipid endpoints, regardless of the presence of background ezetimibe. Importantly, the safety profile of NEXLETOL was similar with or without background ezetimibe therapy.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Largest borrow rate increases among liquid names » 08:45
03/26/20
03/26
08:45
03/26/20
08:45
TXMD

TherapeuticsMD

$1.28 /

+0.1 (+8.47%)

, SKT

Tanger Factory

$7.17 /

+0.77 (+12.03%)

, SSO

ProShares Ultra S&P 500

$82.06 /

+2.057593 (+2.57%)

, ESPR

Esperion

$37.33 /

-0.66 (-1.74%)

, AG

First Majestic

$7.40 /

+0.18 (+2.49%)

, CNXM

CNX Midstream Partners

$8.21 /

+0.15 (+1.86%)

, BE

Bloom Energy

$5.32 /

-0.315 (-5.59%)

, HEXO

Hexo

$0.75 /

+0.0964 (+14.75%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Direxion Oil & Gas 3x Bear ETF (DRIP) 18.40% +0.80, TherapeuticsMD (TXMD) 34.97% +0.64, Tanger Factory (SKT) 8.38% +0.51, ProShares Ultra S&P 500 (SSO) 2.20% +0.42, Esperion (ESPR) 1.20% +0.34, First Majestic Silver (AG) 1.35% +0.27, CNX Midstream Partners (CNXM) 17.06% +0.25, Bloom Energy (BE) 3.81% +0.19, Precigen (PGEN) 12.55% +0.17, and Hexo Corp (HEXO) 63.50% +0.16.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion announces presentations on NEXLETOL program, NEXLIZET study » 07:42
03/23/20
03/23
07:42
03/23/20
07:42
ESPR

Esperion

$34.21 /

-2.79 (-7.54%)

Esperion announced that…

Esperion announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 study of NEXLIZET will be presented at the American College of Cardiology's 69th Scientific Session Together with World Congress of Cardiology on March 28th - 30th 2020. Esperion completed its global, pivotal, Phase 3 LDL-C lowering development program and announced positive cumulative results in October 2018. The program evaluated the safety, tolerability and LDL-C lowering efficacy of NEXLETOL and NEXLIZET in patients with hypercholesterolemia who either have atherosclerotic cardiovascular disease or are at high risk of ASCVD, and who continue to have elevated levels of LDL-C despite the use of maximally-tolerated statins and ezetimibe, leaving them at high risk for cardiovascular events. The program included over 4,000 patients across five studies, four for NEXLETOL and one for NEXLIZET. Esperion also completed a Phase 2 study and announced positive topline results in August 2019. The study evaluated the efficacy and safety of NEXLIZET compared to ezetimibe and placebo in 179 patients with both hypercholesterolemia and type 2 diabetes. Patients enrolled were on stable background diabetes medications and washed out of other lipid modifying therapies.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion appoints Alan Fuhrman to board of directors » 07:46
03/18/20
03/18
07:46
03/18/20
07:46
ESPR

Esperion

$30.73 /

+3.36 (+12.28%)

Esperion announced the…

Esperion announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. Alan is currently CFO of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Citi upgrades Esperion to Buy on attractive valuation after pullback » 06:59
03/17/20
03/17
06:59
03/17/20
06:59
ESPR

Esperion

$27.37 /

-6.97 (-20.30%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty upgraded Esperion Therapeutics to Buy from Neutral with a price target of $46, down from $82. As a standalone company, Esperion can surpass the launch expectations currently priced in the stock, Beatty tells investors in a research note. Further, in the event that the bempedoic acid launch disappoints, the potential for the company to be acquired limits downside from here, adds the analyst. With the stock down 61% since February 19, Beatty finds Esperion attractively priced heading into the launch of bempedoic acid later this month.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Esperion upgraded to Buy from Neutral at Citi » 04:56
03/17/20
03/17
04:56
03/17/20
04:56
ESPR

Esperion

$27.37 /

-6.97 (-20.30%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty upgraded Esperion Therapeutics to Buy from Neutral.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.